Eurofins trims 2026 growth outlook. Eurofins stock holds EUR 14.9 billion value

Published on 10/26/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month sales reached EUR 5.614 billion, up 3.7 percent, on October 21, 2026. Eurofins stock costs EUR 85.93 on October 26, 2026.

Growth and portfolio repositioning

Eurofins reported EUR 5.614 billion in nine-month sales on October 21, 2026.
Organic growth reached 3.5 percent in the third quarter of 2026.
Eurofins stock trades at EUR 85.93 at 10:17 a.m. CEST at Lang & Schwarz on October 26, 2026.
Eurofins will hold its next investor event on November 11, 2026.

Aquarellillustration der Altstadt und Skyline von Luxembourg mit Fluss und Brücken — Aquarellmalerei von Luxembourg symbolisiert den Sitz von Eurofins Scientific SE, ISIN FR0014000MR3, in Pastelltönen, Illustration mit AI erstellt.

Eurofins stock (ISIN FR0014000MR3) is trading at EUR 85.93 at Lang & Schwarz on October 26, 2026 at 10:17 a.m. CEST. The laboratory group trimmed its 2026 organic-growth objective in its nine-month update published on October 21, 2026, while keeping its profitability objectives unchanged, according to Eurofins.

Revenue reaches EUR 5.614 billion

Reported revenue rose 3.7 percent to EUR 5.614 billion in the first nine months of 2026. Organic growth reached 3.0 percent for the period and accelerated from 2.5 percent in the first quarter to 3.0 percent in the second quarter and 3.5 percent in the third quarter, according to MarketScreener.

The improvement was uneven across the portfolio. In the nine-month period, Europe generated EUR 2.946 billion with 1.9 percent organic growth, North America produced EUR 2.046 billion with 2.8 percent growth, and the rest of the world delivered EUR 621 million with 9.3 percent growth.

What does 3.5 percent growth mean?

The third-quarter acceleration gives Eurofins a stronger operating base, but it did not restore the original full-year organic-growth objective. Management expects acquisition revenue in 2026 to exceed the previous annual objective of EUR 250 million, while the adjusted EBITDA margin objective for 2027 remains 24 percent, compared with 22.5 percent in fiscal year 2025, according to Investing.com.

Three dates frame the repositioning

On October 1, 2026, Eurofins completed its acquisition of Element Materials Technology's North American Life Sciences Testing business for an enterprise value of USD 400 million. On October 1, 2026, it also completed the divestment of its Electrical and Electronic Testing business to UL Solutions for an enterprise value of EUR 575 million. On October 21, 2026, the nine-month update combined 3.7 percent reported growth with a lower 2026 organic-growth expectation, according to Eurofins.

Next investor date is November 11

Eurofins lists its next investor event for November 11, 2026, in Toronto, Canada. The company also held an investor event on October 23, 2026, in Amersfoort, Netherlands, according to Eurofins.

Eurofins stock stays tied to execution

The current valuation places the focus on whether accelerating quarterly organic growth can offset the weaker full-year demand outlook. Eurofins has 65,000 employees and operates more than 950 laboratories, according to its company profile.

Eurofins stock was trading at EUR 85.93 at Lang & Schwarz on October 26, 2026 at 10:17 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.